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Lafora progressive myoclonus epilepsy (Lafora disease, LD) is a 
fatal autosomal recessive neurodegenerative disorder (with an onset 
in teenage years in previously normal adolescents). This paper 
represents a view of a patient diagnosed with Lafora progressive 
myoclonus epilepsy, over a course of seven years. A description of 
the initial manifestation of symptoms, doctors’ attempts to combat 
the symptoms with drug treatment, further attempts towards reaching 
the correct diagnosis, the final confirmation of the Lafora diagnosis 
(mutation in the NHLRC1 gene), and the current state of the patient 
is presented. The absence of a positive family history, the lack of 
staff specialized in dealing with this or similar pathology, and the 
diagnostic inability to characterize this type of disorder in Bosnia and 
Herzegovina have led to a fair delay in diagnosing and beginning of an 
adequate pharmacological treatment. Overall, recent identification of 
LD cases in Bosnia and Herzegovina warrants an establishment of a 
Centre for Genetic Testing in order to ensure more humane counseling 
of an entire family whose family member(s) might be diagnosed with 
this devastating and currently an incurable disorder.
Keywords: Progressive myoclonus epilepsy; Lafora disease; NHLRC1 
mutation
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Introduction
This paper represents a view of a patient diagnosed 
with Lafora progressive myoclonus epilepsy 
(Lafora disease, LD), over a seven-year-long 
period, including the beginning of symptoms, 
the attempts to combat the symptoms with drug 
treatment, the attempts at reaching the correct 
diagnosis, the confirmation of the diagnosis 
(mutation in the NHLRC1 gene), and the current 
state of the patient. Parents as legal representative 
signed informed consent. Local ethical approval 
for case presentation was obtained.
Case report
In Apr 2008, a 9-yr-old girl with initials A.S. (born 
in 1999, in Maglaj, Bosnia and Herzegovina) was 
admitted into the General Hospital Tesanj (Tesanj, 
Bosnia and Herzegovina) with a severe headache, 
mental confusion, high fever, and a cough. Neither 
the patient’s own medical history nor that of her 
family contained details of any specific disorder. 
Both her birth weight (3850 gr) and her birth 
length (58 cm) were considered normal. Prior to 
that admission to the hospital, she manifested no 
cognitive disabilities. She was diagnosed with 
having epilepsy with mental disorientation and she 
was treated with phenobarbitone, sodium valproate, 
and lamotrigine. Then, in 2010, she started having 
seizures: they would begin with nausea, impaired 
vision, and a loss of consciousness. During the 
seizures, her eyes were tightly closed and she 
exhibited no twitching of her legs nor her arms. 
After ten to thirty min, the patient would regain 
consciousness and would complain of feeling cold 
at the terminal part of extremities. Additionally, 
she would feel pain in her ankles, with bruising 
joints, after which the pain would progress towards 
her toes, followed by swelling and reddening. 
Magnetic resonance imaging (MRI) of the patient’s 
head showed no apparent changes in the structure 
of the patient’s brain. 
During the third year following the onset of 
her symptoms and her first seizure, the patient 
experienced a different type of “seizure” during 
her sports class: she began to walk aimlessly and 
insecurely, with tottering, she had a fixed gaze, 
pale face, and was rambling (calling a friend by 
her name over and over again). However, she did 
not lose her balance and did not fall. In addition, 
she manifested no twitching of extremities. That 
particular “seizure” lasted for about ten minutes, 
after which she regained consciousness. However, 
following that particular seizure the patient failed 
to re-establish her previous state: she had absent 
gaze, difficulty using cutlery, she lost her sense 
in space and time, and she did not recognize her 
parents and people she previously knew around her. 
On one occasion, she had a generalized epileptic 
seizure.
In July 2011, the patient experienced a sudden 
loss of consciousness, and she lost her balance 
and fell, her body becoming rigid and cyanotic, 
without twitching of the extremities, while her 
eyes were closed. At the time, the patient’s pupils 
were round, symmetrical, with proper response to 
light. Following recovery from this seizure, the 
patient had difficulty walking independently; she 
walked aided and her walk was atactic (suggesting 
a lack of muscle coordination), with significant 
deviation to the left. She also had difficulty in 
performing a walk on heels and toes and could 
not walk in a straight line. Dystonia of torso and 
extremities was present. Romberg was unstable, 
with a deviation to the left. Finger to nose test was 
abnormal (suggesting dysmetria). Gross motor 
abilities test was in order. Muscle tendon reflex 
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(MTR) was symmetrical, live. Right, Babinski 
sign was positive. Lumbar puncture test, as well 
as findings of ophthalmologists and cardiologists, 
were without noticeable pathologies. Hormonal 
status of the patient was within the normal range. 
An electroencephalogram test (EEG) showed 
continuously discharging of the high voltage 
Delta Theta activity with interposed sharp and 
steep waves of high voltage and paroxysmal high 
voltage spikes, as well as multiple spike-and-wave 
discharges. During the stay at the hospital, the 
EEG registration did not change. The patient was 
subjected to additional MRI scans which revealed 
no apparent changes in the brain structure. Seizures 
were classified as visually partial twitches, 
eventually becoming myoclonic, and generalized 
tonic-clonic twitching. At this time, the patient 
exhibited evident cognitive deterioration. No 
cranial nerve deficits were present, but rapid 
irregular myoclonic twitches that were palpable at 
rest were present and were increased by voluntary 
movements of the upper limbs. There was no sign 
of Babinski. The patient was able to cooperate with 
the doctor during the examination. In addition, the 
patient was decelerated with a little verbal and 
motor activity.
Genetic testing was carried out in Genoa, Italy, 
on Mar 2013, from the DNA that was extracted 
from leukocytes of peripheral blood. Analysis 
of exons 1-4 of the EPM2A gene (NM_005670) 
and the single exon, exon 1, of the NHLRC1 
gene (NM_198586), using direct sequencing, 
was performed. Multiplex Ligation-dependent 
Probe Amplification (MLPA) method was used 
to examine the genes and the genomic region that 
includes the region from exons 1 and 4 of the 
EPM2A gene and exon 1 of the NHLRC1 gene. 
The genetic testing identified that the patient is the 
carrier of the homozygous 1-bp deletion, 990G, 
within the NHLRC1 gene. Following the result of 
the genetic testing, clonazepam was included in 
the patient’s therapy. 
In July 2015, levetiracetam was added to the 
therapy. In May 2015, treacheostoma was placed, 
as well as percutaneous endoscopic gastrostomy. 
Currently, (Apr 2017), the patient is bedridden, in 
a continuous horizontal position, with the rapid 
irregular myoclonic twitches noticeable at rest, and 
increased by voluntary movements of the upper 
limbs. Furthermore, the patient also experiences 
frequent episodes of fever, which is insensitive to 
antipyretics.
Discussion
Lafora progressive myoclonus epilepsy is a fatal 
autosomal recessive neurodegenerative disorder 
(with an onset in teenage years in previously 
normal adolescents (1), although there are reports 
of cases of the illness being diagnosed in patients 
in their mid-twenties (2)) characterized by the 
presence of glycogen-like intracellular inclusions 
called Lafora bodies (majority of patients carry 
mutations in either the EPM2A or EPM2B (also 
termed NHLRC1 gene) genes, encoding laforin, 
a glucan phosphatase, and malin, an E3 ubiquitin 
ligase, respectively) (3). 
In LD, gene carriers are asymptomatic, and in 
family history, there are usually no examples of 
any disease with similar symptoms. It is relatively 
common in the Mediterranean part of Spain, France, 
and Italy, in restricted regions of central Asia, India, 
Pakistan, northern Africa, and the Middle East, in 
ethnic isolates from the southern United States and 
Quebec (4). In addition to the case of LD described 
herein, two sibling cases of LD were registered 
in Bosnia and Herzegovina in 2006 and 2007. 
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In general, diagnosis of LD is based on clinical 
examination, the EEG findings, as well as genetic 
testing of two genes that are associated with LD: 
EPM2A or EPM2B (NHLRC1). The diagnosis 
of LD in developing countries could be made by 
skin and axillary sweat gland biopsy (eccrine or 
apocrine) by periodic acid-Schiff stain which is 
more affordable (detection of Lafora bodies). Lafora 
bodies can also be detected in the brain, liver, skin, 
or muscle tissue, anterior pituitary, hypothalamus, 
and pancreas (5, 6). LD is characterized by 
fragmentary, symmetric, or generalized myoclonus 
and/or generalized tonic-clonic seizures, visual 
hallucinations (occipital seizures), and progressive 
neurologic degeneration, including cognitive and/
or behavioral deterioration, dysarthria, and ataxia 
beginning in previously healthy adolescents (4).
 In the case presented herein, despite of three-year 
long wandering in the establishing of the correct 
diagnosis, the initial success in the treatment 
was nevertheless achieved by pharmacological 
treatment of the patient’s disease symptoms. With 
the progression of the disease, as time passed, 
the success of the therapy was at a diminished 
level. The absence of a positive family history, 
the lack of staff specialized in dealing with this or 
similar pathology, and the diagnostic inability to 
characterize this type of diagnosis in Bosnia and 
Herzegovina have led to a fair delay in diagnosing 
and beginning of the adequate pharmacological 
treatment. Currently, there is no specific treatment 
for LD; however, commonly used antiepileptic 
therapy (palliative treatment) for the management 
of myoclonus may improve symptoms in the 
early stages of the disease (combinations that 
include valproate, phenobarbital, benzodiazepines, 
piracetam, levetiracetam, and zonisamide are 
useful for symptomatic treatment) (7,8). 
In Conclusion
LD is a rare progressive myoclonus epilepsy, 
with a very uncertain and poor prognosis, and 
only treatment of symptoms can be carried out, 
and it requires a multidisciplinary approach in 
the treatment and understanding of the overall 
community. Recent identification of LD cases in 
Bosnia and Herzegovina warrants an establishment 
of a Centre for Genetic Testing in order to ensure 
more humane counseling of an entire family whose 
family member(s) might be diagnosed with this 
devastating and currently an incurable disorder.
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